Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dth.15255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biologic drugs induced vitiligo: case reports and review of literature.
Front Immunol
January 2025
Department of Dermatology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Biological drugs are extensively used to treat various inflammatory diseases, including psoriasis, atopic dermatitis (AD), and rheumatoid arthritis. While generally effective and safe, these therapies have been increasingly associated with secondary development of vitiligo, especially with anti-TNF α and anti-IL17 drugs. Dupilumab, an IL-4 receptor alpha antagonist used in moderate to severe AD, rarely induces vitiligo.
View Article and Find Full Text PDFThe off-label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab-induced erythrodermic psoriasiform dermatitis. A modified, spaced dupilumab dosing regimen, combined with cyclosporine, successfully managed both conditions, offering a promising strategy for managing dupilumab adverse effects while maintaining control over chronic actinic dermatitis.
View Article and Find Full Text PDFSuccessful treatment of the dupilumab-induced psoriatic dermatitis/arthritis and atopic dermatitis with a JAK inhibitor: A case report and literature review.
J Allergy Clin Immunol Glob
November 2024
Department of Dermatology, National Hospital Organization Saitama Hospital, Saitama, Japan.
Dupilumab-induced psoriatic dermatitis and arthritis in a patient with atopic dermatitis were effectively managed with upadacitinib, highlighting the use of Janus kinase inhibitors as a possible treatment for biologic therapy side effects.
View Article and Find Full Text PDFJanus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis.
Case Rep Dermatol
June 2024
Department of Dermatology and Venerology, University Hospital Basel, Basel, Switzerland.
Introduction: After the introduction of dupilumab as systemic treatment for atopic dermatitis, an increasing number of patients have been successfully treated. However, reports of patients developing psoriasis as a secondary skin condition have been accumulating. The most likely reason is assumed to be an immune shift from Th2- to Th1-mediated auto-inflammatory processes.
View Article and Find Full Text PDFA pediatric case of dupilumab-induced pustular psoriasis.
J Dermatolog Treat
December 2024
Department of Dermatology, Children's Hospital of Zhejiang University School of Medicine, Hangzhou.
Dupilumab is a novel treatment agent for moderate to severe atopic dermatitis (AD) with few adverse effects. Drug-induced psoriasiform lesions are rare. We report a 4-year-old boy with AD who developed pustular psoriasis during treatment with dupilumab.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!